Deep dives · Initiation
Galectin Therapeutics: a $367M value resting on a subgroup result and an unfunded Phase 3
Belapectin missed its primary endpoint on the full analysis set, and nobody has yet funded Phase 3. We value belapectin at $1.70 per share and initiate at Sell.
The full 40-page report
Sign in to read the complete analysis, estimates and model detail.
Key takeaways
- New varices were 10.1% vs 17.8% on placebo on the full analysis set (p=0.13); the positive reading is per-protocol
- Cash is $13.3M against $2.4M to $4.0M of quarterly burn, and the filing discloses substantial doubt about going concern
- At our 31% success rate, peak sales must reach $3.7B to justify the price; our base case is $0.9B
- Initiate at Sell with a $1.70 target, 53% below the price
Investment thesis
Belapectin missed its Phase 2b/3 primary endpoint on the full analysis set, and the positive reading is per-protocol. A $367M market value rests on that subgroup result and a Phase 3 nobody has yet funded.
Valuation
Our $1.70 target is a probability-weighted value: bear $0.00, base $0.92 and bull $6.47, weighted 35/45/20%. We set Phase 3 success at 31% against a 52% industry base rate.
Risks to our view
- Phase 3 fails or repeats the NAVIGATE result
- A funding gap before Phase 3: $13.3M of cash against a $110M budget, with $30M of notes due 30 Jun 2027
- Dilution: a partner or about $55M of equity (+19% shares) is likely needed within roughly 12 months